Valuation, from the filing
| Public float | $65.47B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-03-31 |
|---|---|---|
| Float per share | $229.39 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 39.0× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 3.0× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 2.6× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-03-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-09-30 — the year that filing covered.
Valuation over time
39.0× earnings today, against a median of 42.0× across 10 years on record. In line with its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-03-31 | $65.47B | 39.0× | |
| 2024-03-31 | $71.46B | 41.9× | |
| 2023-03-31 | $70.25B | 47.3× | |
| 2022-03-31 | $74.87B | 42.1× | |
| 2021-03-31 | $70.62B | 33.8× | |
| 2020-03-31 | $62.36B | 71.4× | |
| 2019-03-31 | $67.28B | 54.6× | |
| 2018-03-31 | $56.90B | 183.0× | |
| 2017-03-31 | $39.07B | 35.5× | |
| 2016-03-31 | $32.18B | 33.0× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| SBC / revenue | 1.2% | 13th | |
| Operating margin | 11.8% | 84th | |
| Current ratio | 1.11x | 16th | |
| Net margin | 7.7% | 80th | |
| Gross margin | 45.4% | 24th | |
| R&D / revenue | 5.8% | 27th | |
| Effective tax rate | 10.8% | 29th | |
| Long-term debt / equity | 0.69x | 68th | |
| Revenue YoY growth | 8.2% | 34th | |
| CapEx / revenue | 3.5% | 51th |
BECTON DICKINSON & CO (BDX) reported revenue of $23.25B and net income of $941.00M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BECTON DICKINSON & CO’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $23.25B |
| Cost of revenue | $12.34B |
| Gross profit | $10.91B |
| Operating income | $2.48B |
| Net income | $941.00M |
| Research & development | $1.37B |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $1.96B |
| Income tax expense | $241.00M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $5.71B |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $708.00M |
| Total assets | $50.73B |
| Current assets | $8.14B |
| Total liabilities | Unavailable |
| Current liabilities | $9.40B |
| Total equity incl. NCI | $24.42B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $3.32B |
| Accounts receivable | $2.36B |
| Goodwill | $25.94B |
| Long-term debt | $13.51B |
| Accounts payable | Unavailable |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | Unavailable |
| Capital expenditures | $753.00M |
| Investing cash flow | Unavailable |
| Financing cash flow | Unavailable |
| Net change in cash | $146.00M |
| Stock-based compensation | $283.00M |
| Common dividends paid | Unavailable |
| Common share repurchases | $2.50B |
| Depreciation & amortization | $2.50B |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | Unavailable |
| Gross margin | 46.9% |
| Operating margin | 10.7% |
| FCF margin | Unavailable |
| SBC / revenue | 1.2% |
| Current ratio | 0.87x |
| Revenue YoY growth | 17.4% |
| Net margin | 4.0% |
| R&D / revenue | 5.9% |
| CapEx / revenue | 3.2% |
| Long-term debt / equity | 0.55x |
| Effective tax rate | 12.3% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BDX in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.